Partial agonism in the D2/AC5 cAMP assay
Cell-based study · HEK cells stably expressing long-form dopamine D2 receptor and adenylyl cyclase 5 (HEK-AC5/D2). [1]
Aripiprazole partially inhibited forskolin-stimulated cAMP accumulation. Its maximal effect was 48 ± 9% of dopamine’s response; potency and efficacy are specific to this cellular reporter system.
| Endpoint | Reported result | Reference |
|---|---|---|
| Inhibition of forskolin-stimulated cAMP accumulation | EC50 4.1 nM (95% CI 0.6–30 nM) | [1] |
| Maximal inhibition relative to dopamine response | Maximal effect 48 (±9)% of dopamine response (standard error) | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration-response experiment; EC50 is a fitted endpoint, not a fixed treatment concentration.
- Exposure duration
- 1 h at room temperature during cAMP accumulation.
- Method
- cAMP assay with 3 µM forskolin and 0.5 mM IBMX; dopamine and quinpirole reference agonists.
- Reported limits
- Assay drug vehicle and exact replicate count beyond at least three independent experiments in duplicate were not reported in the read methods. Nominal dose series not transcribed.
Methods and source locations
Compound reported in the paper: Aripiprazole
Evidence applies to the reported research material; no salt conversion, current Adooq lot equivalence, or clinical efficacy inferred.
Methods 2.1–2.3, 2.7; Results 3.1; Figure 1 and Table 1 (Gαi/o columns)
Inhibition of forskolin-stimulated cAMP accumulation: cAMP quantified with Cisbio dynamic 2 assay; at least three independent experiments conducted in duplicate. — Table 1, aripiprazole row, Gαi/o EC50; Methods 2.3 and 2.7
Maximal inhibition relative to dopamine response: Table 1 reports standard errors; dopamine reference maximum 100 (±3)%. — Table 1, aripiprazole and dopamine rows, Gαi/o Max; Figure 1